Physician profile
Nelson H Lim
NPI 1366463168
$10,332.49
in general payments reported to CMS, 2019-2025
25 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $95.34 · 2021: $26.70 · 2022: $8,402 · 2023: $427 · 2024: $142 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $825 · Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $825.00 |
| Food and Beverage | $643.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $8,000.00 | 2022 | |
| Olympus Medical Systems Corporation | $825.00 | 2025 | Disposable Hot Biopsy Forceps |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.44 | 2019-2024 | Trulance |
| Janssen Biotech, INC. | $175.31 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Abbvie INC. | $132.51 | 2019-2025 | |
| Celgene Corporation | $120.62 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $106.74 | 2022-2023 | Dupixent |
| Gilead Sciences, INC. | $102.92 | 2019-2023 | |
| Pfizer INC. | $96.16 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.88 | 2020-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $70.71 | 2022-2024 | Rebyota |
| Ardelyx, INC. | $60.40 | 2022-2023 | Ibsrela |
| Ucb, INC. | $54.38 | 2019 | |
| Madrigal Pharmaceuticals | $38.43 | 2025 | Rezdiffra |
| Qol Medical, LLC | $30.30 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $30.05 | 2019-2022 | |
| Digestive Care, INC. | $26.01 | 2022 | |
| Genzyme Corporation | $24.57 | 2023 | |
| Lucid Diagnostics INC. | $20.92 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.46 | 2024 | Voquezna |
| Shionogi INC | $16.38 | 2019 | |
| Allergan, INC. | $14.75 | 2019 | |
| Echosens North America, INC. | $14.66 | 2024 | Fibroscan |
| Medtronic, INC. | $13.11 | 2022 | |
| W. L. Gore & Associates, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.